Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: biao luo who wrote (3174)	12/6/1997 9:52:00 PM
From: JOHN W.	Read Replies (2) \| Respond to of 6136

Freaking wrong and another bullshoot lie by those that will prosper trying to kill this company. Think about what you are saying, This big pharmaceutical company (Lilly) has a drug that they have develop and it is in their library, and then sought out this little biotechb to develop the product through clinical trial while paying them money to do so, and then sharing the profits for it's sales????? Why, because Lilliy was too busy? What did Lilly need AGPH for?? So then Lilly abandons their own drug and allows AGPH to develop it. So what happened, AGPH pay liliiy off for their drug? In a recent tech letter, I read that Glaxo was not impressed with the 70% response to VX-478 nad was planning to withdraw from the collaboration. And since you are a VRTX shareholder, do you also believe protease inhibitors will be obsolete in 5 yrs?

To: biao luo who wrote (3174)	12/6/1997 10:27:00 PM
From: Izzy	Read Replies (3) \| Respond to of 6136

Biao, what was your point in posting on the AGPH thread and then reposting your note on the VRTX thread? Are you trying to score kudos from someone? If you have concrete info and documentation to support your statements, then post the article here so that we call all read it. Otherwise, it appears that you are providing misinformation. With an estimated 30% failure rate of the VRTX PI so far (besides the high reported drug side-effects), I understand that VRTX/GLX cannot even get people to enroll in its USA clinical trials. Their drug is a dog and you know it. I even doubt that it will come to market, and, if it does, I sure as hell won't prescribe it unless there is clear proof that it is a superior PI to all others on the market at that time, which I seriously doubt. I had owned VRTX but sold to buy AGPH. You don't even own AGPH. So, bug off or post something that is truthful and documented.